Profilo
Charlotta Gauffin is currently Chief Scientific Officer at Dicot Pharma AB since 2022.
Former positions include Head-Clinical Trial Management at LIDDS AB from 2019 to 2022, and Manager-Clinical Project & Program Director at Medivir AB, Biovitrum AB, and Galderma Holding AB. Education includes graduate and doctorate degrees from the University of Uppsala.
Posizioni attive di Charlotta Gauffin
| Società | Posizione | Inizio |
|---|---|---|
| DICOT PHARMA AB | Direttore Tecnico/Scientifico/R&S | 11/07/2022 |
Precedenti posizioni note di Charlotta Gauffin
| Società | Posizione | Fine |
|---|---|---|
| LIDDS AB | Direttore Tecnico/Scientifico/R&S | 01/07/2022 |
Galderma Holding AB | Direttore Tecnico/Scientifico/R&S | - |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Direttore Tecnico/Scientifico/R&S | - |
| MEDIVIR AB | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Charlotta Gauffin
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Medivir AB
Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Commercial Services |
University of Uppsala
University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LIDDS AB
LIDDS AB Pharmaceuticals: MajorHealth Technology Focuses on the development of treatment alternatives and hormonal therapy for prostate cancer | Health Technology |
Galderma Holding AB | |
Dicot Pharma AB
Dicot Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs to treat erectile failure | Health Technology |
















